Adaptive Biotechnologies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Adaptive Biotechnologies 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. 

CEO
Chad Robins
CEOChad Robins
Employees
624
Employees624
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
2009
Founded2009
Employees
624
Employees624

ADPT Key Statistics

Market cap
4.18B
Market cap4.18B
Price-Earnings ratio
-61.98
Price-Earnings ratio-61.98
Dividend yield
—
Dividend yield—
Average volume
2.44M
Average volume2.44M
High today
$25.86
High today$25.86
Low today
$24.66
Low today$24.66
Open price
$25.47
Open price$25.47
Volume
1.95M
Volume1.95M
52 Week high
$30.74
52 Week high$30.74
52 Week low
$12.00
52 Week low$12.00

Stock Snapshot

With a market cap of 4.18B, Adaptive Biotechnologies(ADPT) trades at $25.65. The stock has a price-to-earnings ratio of -61.98.

During the trading session on 2026-10-14, Adaptive Biotechnologies(ADPT) shares reached a daily high of $25.86 and a low of $24.66. At a current price of $25.65, the stock is +4.0% higher than the low and still -0.8% under the high.

Trading volume for Adaptive Biotechnologies(ADPT) stock has reached 1.95M, versus its average volume of 2.44M.

The stock's 52-week range extends from a low of $12.00 to a high of $30.74.

The stock's 52-week range extends from a low of $12.00 to a high of $30.74.

ADPT News

Investing.com 9h
Adaptive Biotechnologies COO Julie Rubinstein sells $919,870 in stock - Investing.com

...

Adaptive Biotechnologies COO Julie Rubinstein sells $919,870 in stock - Investing.com
TipRanks 20h
Adaptive Biotechnologies price target raised to $32 from $28 at TD Cowen

TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $32 from $28 and keeps a Buy rating on the shares. The firm adjusted targets in th...

Simply Wall St 4d
Adaptive Biotechnologies Could Be 6% Undervalued Following Its ClonoSEQ Growth Narrative

Adaptive Biotechnologies (ADPT) is back on watch after recent share price moves, with the stock last closing at US$26.49. Investors are reassessing the business...

Adaptive Biotechnologies Could Be 6% Undervalued Following Its ClonoSEQ Growth Narrative

Analyst ratings

89%

of 9 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

People also own

Based on the portfolios of people who own ADPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.